Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1.   (Currently Amended) A method of ameliorating symptoms associated with the growth of bone metastasized cancer or bone-originated cancer, comprising administering to an individual in need thereof a medicament comprising an amount of a parathyroid hormone ~~PTH~~ receptor agonist effective to ~~reduce bone loss, reduce bone fracturing, and/or~~ reduce ~~pain.~~;

wherein said agonist comprises at least 25 amino acids and comprises at least 29% identity with SEQ ID NO: 1;

wherein said agonist comprises an activation domain comprising amino acid sequence X1-V-S-E-X2-Q-X3, wherein X1 is selected from S or A, X2 is selected from I or H, and wherein X3 is selected from L or F; and

wherein said agonist comprises an receptor binding domain comprising amino acid sequence L-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13, wherein X4 is selected from R, H, or E, wherein X5 is selected from K, H, or Aib, wherein X6 is selected from K or L, wherein X7 is selected from I or L, wherein X8 is selected from A, Q, or E, wherein X9 is selected from D, E, K, or L, wherein X10 is selected from V, I, or L, wherein X11 is selected from H or Thi, wherein X12 is selected from N or T, wherein X13 is selected from F, A, or Y.

2.   (Withdrawn) The method according to claim 1, wherein said amount is effective to reduce pain.

3.   (Currently Amended) The method according to claim 1, wherein said parathyroid hormone ~~PTH~~ receptor agonist is PTH or an analogue thereof.

4.   (Currently Amended) The method according to claim 3, wherein said parathyroid hormone ~~PTH~~ or an analogue thereof is parathyroid hormone ~~PTH~~ (1-34).

5.   (Currently Amended) The method according to claim 1, wherein said <u>parathyroid hormone</u> PTH receptor agonist is parathyroid hormone-related protein or an analogue thereof.

6.   (Previously presented) The method according to claim 1, wherein said individual has bone metastasized cancer.

7.   (Previously presented) The method according to claim 6, wherein said bone metastasized cancer is breast cancer, prostate cancer, lung cancer, kidney cancer, or thyroid cancer or myeloma.

8.   (Previously presented) The method according to claim 1, wherein said individual has bone-originated cancer.

9.   (Previously presented) The method according to claim 1, wherein said bone originated cancer is sarcoma.

10.   (Currently amended) The method according to claim 1, wherein the amount of the <u>parathyroid hormone</u> PTH receptor agonist is from 0.1 to 1000 micrograms.

11.   (Currently amended) The method according to claim 10, wherein the amount of the <u>parathyroid hormone</u> PTH receptor agonist is from 20 to 200 micrograms.

12.   (Currently Amended) The method according to claim 3, wherein said <u>parathyroid hormone</u> PTH or an analogue thereof is teriparatide acetate.

13.   (Withdrawn) A medicament for ameliorating symptoms associated with the growth of bone metastasized cancer or bone-originated cancer, comprising an amount of a PTH receptor agonist effective to reduce bone loss, reduce bone fracturing, and/or reduce pain in an individual in need thereof.

14.   (Withdrawn) The medicament according to claim 13, wherein said amount is effective to reduce pain.

15.   (Withdrawn) The medicament according to claim 13, wherein said PTH receptor agonist is PTH or an analogue thereof.

16.   (Withdrawn) The medicament according to claim 15, wherein said PTH or an analogue thereof is PTH(1-34).

17.   (Withdrawn) The medicament according to claim 15, wherein said PTH or an analogue thereof is teriparatide acetate.

18.   (Withdrawn) The medicament according to claim 13, wherein said PTH receptor agonist is parathyroid hormone-related protein or an analogue thereof.

19.   (Withdrawn) The medicament according to claim 13, comprising from 0.1 to 1000 micrograms of the PTH receptor agonist.

20.   (Withdrawn) The medicament according to claim 13, comprising from 20 to 200 micrograms of the PTH receptor agonist.

21.   (New) The method of claim 1 wherein the activation domain is selected from the group consisting of amino acids SVSEIQ, AVSEIQ, or AVSEHQ.

22.   (New) The method of claim 1 wherein the receptor binding domain comprises the amino acids selected from the group consisting of LRKKLQDVHNF, LRKKLQDVHNY, LHHLIAEIHTA, LEKLLEKLHNF, LRKLLQDLHNF, LHAibLIAEIHTA, LEKLLEKLThiTA, LEKLLELLHTA, LHHLLAELHTA, LEKLIEKIHTA, or LHHLIAEIHTA.

23.   (New) The method of claim 1 wherein the parathyroid hormone receptor agonist is selected from the group consisting of:

```
SEQIDNO_1        SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNF,
SEQIDNO_2        AVSEIQFMHNLGKHLSSMERVEWLRKKLQDVHNF,
SEQIDNO_3        AVSEHQLLHDKGKSIQDLRRRFFLHHLIAEIHTA,
SEQIDNO_4        AVSEIQFXHNLXKHLSSXERVEXLRKKLQDVHNY,
SEQIDNO_5        SVSEIQLMHNLGKHLNSMERVELLEKLLEKLHNF,
SEQIDNO_6        SVSEIQLMHNLGKHLNSMERVEWLEKKLEKVHNF,
```

```
SEQIDNO_7     SVSEIQLMHNLGKHLNSMERVELLRKLLQDLHNF,
SEQIDNO_8     AVSEHQLLHDKGKSIQDLRRRFFLHXLIAEIHTA,
SEQIDNO_9     AVSEHQLLHDKGKSIQDLRRRELLEKLLEKLXTA,
SEQIDNO_10    AVSEHQLLHDKGKSIQDLRRRELLEKLLELLHTA,
SEQIDNO_11    AVSEHQLLHDKGKSIQDLRRRFLLHHLLAELHTA,
SEQIDNO_12    AVSEHQLLHDKGKSIQDLRRREFLEKLIEKIHTA,
SEQIDNO_13    AVSEIQFXHNLGKHLSSXERVEXLRKKLQDVHNY,
SEQIDNO_14    AVSEIQFXHNLGKHLSSXXRVEXLRKKLQDVHNY,
SEQIDNO_15    AVSEIQFXHNLGKHLSSXXRVEXLRKKLQDVHNY,
SEQIDNO_16    AVSEIQFXHNLGKHLSSXXRVEXLRKKLQDVHNY,
SEQIDNO_17    AVSEIQFXHNLGKHLSXXXRVEXLRKKLQDVHNY,
SEQIDNO_18    AVSEIQFMHNLGKHLXSXERVEWLRKKLQDVHNF,
SEQIDNO_19    AVSEIQFMHNLGKHLSSXEXVEWLRKKLQDVHNF,
SEQIDNO_20    AVSEIQFMHNLGKHLSXXERVEWLRKKLQDVHNF,
SEQIDNO_21    AVSEIQFMHNLGKHLSSXERVEWLRKKLQDVHNF,
SEQIDNO_22    AVSEIQFMHNLGKHLSSXXRVEWLRKKLQDVHNF,
SEQIDNO_23    AVSEIQFMHNLGKHLSXXERVEWLRKKLQDVHNF,
SEQIDNO_24    AVSEIQFMHNLGKHLSSXERVEWLRKKLQDVHNF,
SEQIDNO_25    AVSEIQFMHNLGKHLSSXXRVEWLRKKLQDVHNF,
SEQIDNO_26    AVSEIQFMHNLGKHLSXXERVEWLRKKLQDVHNF,
SEQIDNO_27    AVSEIQFMHNLGKHLSSXXRVEWLRKKLQDVHNF,
SEQIDNO_28    AVSEIQFMHNLGKHLSXXXRVEWLRKKLQDVHNF,
SEQIDNO_29    AVSEIQFMHNLGKHLSXXERVEWLRKKLQDVHNF,
SEQIDNO_30    AVSEIQFMHNLGKHLSSXXRVEWLRKKLQDVHNF,
SEQIDNO_31    AVSEIQFMHNLGKHLSSXXRVEWLRKKLQDVHNF,
SEQIDNO_32    AVSEIQFMHNLGKHLSXXXRVEWLRKKLQDVHNF,
SEQIDNO_33    AVSEIQFMHNLGKHLSXXXRVEWLRKKLQDVHNF,
SEQIDNO_34    AVSEIQFMHNLGKHLSXXXRVEWLRKKLQDVHNF,
SEQIDNO_35    AVSEIQFMHNLGKHLSXXXRVEWLRKKLQDVHNF,
SEQIDNO_36    AVSEIQFMHNLGKHLSXXXRVEWLRKKLQDVHNF,
SEQIDNO_37    AVSEIQFMHNLGKHLSXXXRVEWLRKKLQDVHNF,
SEQIDNO_38    AVSEIQFMHNLGKHLSXXERVEWLRKKLQDVHNF,
SEQIDNO_39    AVSEIQFMHNLGKHLSSXXRVEWLRKKLQDVHNF,
SEQIDNO_40    AVSEIQFMHNLGKHLSXXXRVEWLRKKLQDVHNF,
SEQIDNO_41    AVSEIQFMHNLGKHLSXXXRVEWLRKKLQDVHNF,
SEQIDNO_42    SVSEIQLXHNLXKHLNSXERVEXLRKKLQDVHNY, or
SEQIDNO_43    AVSEHQLLHDKXKSIQDLRRRFFLHHLIAEIHTA.
```